Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Revista de la Sociedad Española del Dolor
versión impresa ISSN 1134-8046
Resumen
ROJAS GONZALEZ, A. Dexmedetomidine as an adjuvant to peripheral nerve block. Rev. Soc. Esp. Dolor [online]. 2019, vol.26, n.2, pp.103-115. Epub 23-Mar-2020. ISSN 1134-8046. https://dx.doi.org/10.20986/resed.2018.3695/2018.
Introduction:
Dexmedetomidine (DEX) is a multifunction drug proposed in recent years as an adjuvant for regional nerve blocks with local anesthetic (LA).
Objetives:
to evaluate the analgesic properties of this α-2 agonist when added to LA in different peripheral nerve block approaches (regional anesthesia), in terms of the quality of the analgesia obtained and potential associated complications.
Materials and methods:
Narrative review, using MeSH terms (English-Spanish), widely-known search engines, considering the last 5 years to date (among other filters), analyzing systematic reviews, meta-analysis or clinical trials comparing nerve blocks with/without perineural DEX added to long-term LA.
Results:
In general terms, it's observed with this selective α-2 agonist, that the blockade latency decreases -19.16 %, increases analgesia duration + 60,79 % and motor blockade + 54,71 %; decreasing postoperative opioids - 49,54 % and LA consumption - 52,00 %, which would be explained by an intrinsic mechanism at perineural level. Its association with cardiovascular depression and sedation (both transient, reversible and without major clinical consequences) is dose-dependent, recommending 0,5-1 μg/kg perineural (maximum 100 μg).
Conclusions:
In terms of risk-benefit, perineural DEX improves the quality of analgesia obtained with minimal associated adverse effects.
Palabras clave : Dexmedetomidine; anesthetics; local analgesia; anesthesia; nerve block.